# Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

> **NCT07286942** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 24 (estimated)

## Conditions studied

- NSCLC
- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** apalolimab and toripalimab (QL1706)

## Key facts

- **NCT ID:** NCT07286942
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2027-12-18
- **Final completion:** 2029-12-18
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07286942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07286942, "Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07286942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*